Abstract 1271P
Background
Understanding the associates and causes of progression after first-line treatment in EGFR-mutant advanced NSCLC remains a critical yet elusive endeavor. In this study, we employed a comprehensive approach integrating machine learning classification and causal inference analysis to unveil the determinants of progression in this patient cohort.
Methods
Retrospective data from eleven academic centers were gathered to compile a cohort of EGFR mutant patients. Classical patient features, treatment characteristics, and the neutrophil to lymphocyte ratio (NLR) at the onset of first-line treatment were analyzed. Fifteen machine learning algorithms were employed to identify the optimal model, evaluated based on F1 score and area under the curve (AUC). Additionally, Linear Non-Gaussian Acyclic Model (LINGAM) was utilized for causal inference analysis to delineate the causal relationships driving progression.
Results
Among 333 patients initially evaluated, 205 cases were deemed suitable for machine learning analysis after accounting for missing data and follow-up duration. Linear discriminant analysis emerged as the most accurate model, achieving an AUC of 0.74 and an F1 score of 0.77. The top three influential variables identified by this model were smoking status, NLR category, and type of first-line treatment with variable importance scores of 1.2, 0.8, and 0.6, respectively. Moreover, LINGAM analysis revealed NLR category, smoking status, and gender as causal factors for progression, with causal estimate scores of -0.20, -0.17, and -0.04, respectively.
Conclusions
This study represents a pioneering effort in utilizing machine learning to explore the determinants of progression after first-line treatment in EGFR-mutant, advanced NSCLC. Our findings underscore the roles of smoking status, NLR category, and type of first-line treatment in driving progression. Furthermore, the causal inference analysis sheds light on smoking status, NLR category, and gender as causally significant factors. This understanding paves the way for elucidating the pathogenesis and developing novel therapeutic strategies for EGFR-mutant advanced NSCLC.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work the authors used ChatGpt 3.5 in order to enhance readibility. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1346P - A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
Presenter: Joseph Murray
Session: Poster session 05
1347P - Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study
Presenter: Zhou Jin
Session: Poster session 05
1348P - First-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the German non-interventional study (NIS) FINN
Presenter: Jonas Kuon
Session: Poster session 05
1349P - A prospective study on clinicians’ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)
Presenter: Francesco Facchinetti
Session: Poster session 05
1350P - Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC
Presenter: Astrid Paulus
Session: Poster session 05
1351P - Heme-oxygenase-1 (HO-1) as a potential biomarker for ICIs in patients with advanced lung cancer
Presenter: Federica Biello
Session: Poster session 05